Your new experience awaits. Try the new design now and help us make it even better

REVIEW article

Front. Immunol.

Sec. Inflammation

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1641132

This article is part of the Research TopicLipid-immune interplay in chronic inflammatory-based disordersView all 9 articles

The NLRP3 Inflammasome: A Pivotal Orchestrator of Multisystem Diseases — From Molecular Mechanisms to Therapeutic Innovation

Provisionally accepted
Shuyan  XiaoShuyan Xiao1,2Yahui  LvYahui Lv1,2Yinming  JiYinming Ji2,3Yi  DongYi Dong1,2Meicen  LiuMeicen Liu2Xiaoran  CuiXiaoran Cui4*Yi  HuYi Hu1*
  • 1Medical school of Chinese PLA, Beijing, China
  • 2Fifth Medical Center of the PLA General Hospital, Beijing, China
  • 3Second Affiliated Hospital of Anhui Medical University, Hefei, China
  • 45th Medical Center of Chinese PLA General Hospital Senior Department of Oncology, Fengtai, China

The final, formatted version of the article will be published soon.

The NLRP3 inflammasome, a key regulatory element in the innate immune system, connects pathogen recognition to chronic disease pathogenesis through modulation of pyroptosis, inflammatory cytokine release, and metabolic homeostasis. Given its central role in inflammatory cascades, this molecular complex has been positioned as a prime therapeutic target. This review delineates pathological contributions of the NLRP3 inflammasome to multisystem disorders—encompassing neurological, cardiovascular, respiratory, gastrointestinal, urological, metabolic, and autoimmune conditions—while systematically evaluating associated therapeutic strategies. Furthermore, classical activation pathways of this molecular complex are consolidated, and targeted inhibition approaches directed against both the inflammasome and its downstream effectors are discussed. Collectively, a critical framework is established for understanding disease mechanisms and advancing translational interventions.

Keywords: NLRP3 inflammasome, pyroptosis, Multisystem diseases, Inflammatory signaling pathways, therapeutic inhibitors

Received: 04 Jun 2025; Accepted: 09 Oct 2025.

Copyright: © 2025 Xiao, Lv, Ji, Dong, Liu, Cui and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Xiaoran Cui, cooboozhi@gmail.com
Yi Hu, huyi301zlxb@sina.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.